(NASDAQ: ABSI) Absci's forecast annual revenue growth rate of 116.18% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Absci's revenue in 2024 is $5,347,000.On average, 5 Wall Street analysts forecast ABSI's revenue for 2024 to be $867,351,741, with the lowest ABSI revenue forecast at $655,885,280, and the highest ABSI revenue forecast at $1,040,369,755. On average, 5 Wall Street analysts forecast ABSI's revenue for 2025 to be $2,667,530,668, with the lowest ABSI revenue forecast at $1,357,004,028, and the highest ABSI revenue forecast at $6,089,216,325.
In 2026, ABSI is forecast to generate $6,929,767,236 in revenue, with the lowest revenue forecast at $5,541,099,781 and the highest revenue forecast at $8,318,434,692.